Johns Hopkins Rheumatology

Home / Research Studies / A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)-SELECT-PsA1

By

IRB: IRB00151158

Purpose of Study: This research study is being done to compare the effectiveness of either 15 or 30 mg once daily of upadacitinib versus adalimumab versus a placebo to control the signs and symptoms of psoriatic arthritis in patients who have failed at least one non-biologic disease modifying anti-rheumatic drug.

Eligibility Criteria:

  • Diagnosed with psoriatic arthritis for at least 6 months
  • Active psoriatic arthritis
  • History of or currently taking a DMARD (e.g. methotrexate, sulfasalazine, leflunomide, or hydroxychloroquine)
  • No history of ever taking a biologic medication
  • Men and women 18 years and older

Study Status:

Recruiting

Coordinator/Contact:

Marilyn C. Towns, BSc, CCRP
(410) 550-2400

Principal Investigator:

Ana-Maria Orbai, MD, MHS
Assistant Professor of Medicine

Dr. Orbai joined the Johns Hopkins Arthritis Center and is actively involved in patient care with a predominant focus on psoriatic arthritis and rheumatoid arthritis. Her research efforts seek to understand, from patients, how they experience arthritis in their lives. This knowledge will build the foundation for choosing and designing measures of disease activity and health related quality of life measures that can be used to improve the care and outcomes of people with arthritis.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.